Uterine sarcoma: Difference between revisions
No edit summary |
|||
| Line 22: | Line 22: | ||
Women who take long-term [[tamoxifen]] are at higher risk. <ref>[http://www.cancer.gov/cancertopics/types/uterinesarcoma] [[National Cancer Institute]] information, accessed 03-11-2006</ref> | Women who take long-term [[tamoxifen]] are at higher risk. <ref>[http://www.cancer.gov/cancertopics/types/uterinesarcoma] [[National Cancer Institute]] information, accessed 03-11-2006</ref> | ||
=== | ==Risk Factors== | ||
* The only documented etiologic factor in 10% to 25% of these malignancies is prior pelvic radiation therapy, which is often administered for benign uterine bleeding that began 5 to 25 years earlier. | |||
* An increased incidence of uterine sarcoma has been associated with tamoxifen in the treatment of breast cancer.<ref>{{Cite web | title =uterine sarcoma| url=http://www.cancer.gov/types/uterine/hp/uterine-sarcoma-treatment-pdq#link/_87_toc}}</ref> | |||
===Drug Side Effect=== | ===Drug Side Effect=== | ||
Revision as of 14:19, 3 September 2015
|
WikiDoc Resources for Uterine sarcoma |
|
Articles |
|---|
|
Most recent articles on Uterine sarcoma Most cited articles on Uterine sarcoma |
|
Media |
|
Powerpoint slides on Uterine sarcoma |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Uterine sarcoma at Clinical Trials.gov Trial results on Uterine sarcoma Clinical Trials on Uterine sarcoma at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Uterine sarcoma NICE Guidance on Uterine sarcoma
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Uterine sarcoma Discussion groups on Uterine sarcoma Patient Handouts on Uterine sarcoma Directions to Hospitals Treating Uterine sarcoma Risk calculators and risk factors for Uterine sarcoma
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Uterine sarcoma |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
A uterine sarcoma is a malignant tumor that arises from the smooth muscle or connective tissue of the uterus. If the lesion originates from the stroma of the uterine lining it is an endometrial stromal sarcoma, and if the uterine muscle cell is the originator the tumor is a uterine leiomyosarcoma. A lesion that also contains malignant tumor cells of epithelial origin is termed uterine carcinosarcoma (formerly called malignant mixed mesodermal/mullerian tumor).
Classification
- Cellular Classification of Uterine Sarcoma.
- The most common histologic types of uterine sarcomas include:
- Carcinosarcomas (mixed mesodermal sarcomas [40%–50%]).
- Leiomyosarcomas (30%).
- Endometrial stromal sarcomas (15%).
The uterine neoplasm classification of the International Society of Gynecologic Pathologists and the World Health Organization uses the term carcinosarcomas for all primary uterine neoplasms containing malignant elements of both epithelial and stromal light microscopic appearances, regardless of whether malignant heterologous elements are present.
Histology
Tumoral entities include leiomyosarcomas, endometrial stromal sarcomas, carcinosarcomas and "other" sarcomas.[1]
- If the lesion originates from the stroma of the uterine lining it is an endometrial stromal sarcoma.
- If the uterine muscle cell is the originator the tumor is a uterine leiomyosarcoma.
- Carcinosarcomas comprise both malignant epithelial and malignant sarcomatous components.
Prevalence
The vast majority of malignancies of the uterine body are endometrial carcinomas - only about 4% will be uterine sarcomas.[2] Generally, the cause of the lesion is not known, however patients with a history of pelvic radiation are at higher risk. Most tumors occur after the menopause. Women who take long-term tamoxifen are at higher risk. [3]
Risk Factors
- The only documented etiologic factor in 10% to 25% of these malignancies is prior pelvic radiation therapy, which is often administered for benign uterine bleeding that began 5 to 25 years earlier.
- An increased incidence of uterine sarcoma has been associated with tamoxifen in the treatment of breast cancer.[4]
Drug Side Effect
Signs and Symptoms
Unusual or postmenopausal bleeding may be a sign of a malignancy including uterine sarcoma and needs to be investigated. Other signs include pelvic pain, pressure, and unusual discharge. A nonpregnant uterus that enlarges quickly is suspicious. However, none of the signs are specific. Specific screening test have not been developed; a Pap smear is a screening test for cervical cancer and not designed to detect uterine sarcoma.
Diagnosis
Investigations by the physician include imaging (ultrasound, CAT scan, MRI) and, if possible, obtaining a tissue diagnosis by biopsy, hysteroscopy, or D&C. Ultimately the diagnosis is established by the histologic examination of the specimen. Typically malignant lesions have >10 mitosis per high power field. In contrast a uterine leiomyoma as a benign lesion would have < 5 mitosis per high power field.
Staging
Uterine sarcoma is staged like endometrial carcinoma at time of surgery using the FIGO cancer staging system.
- Stage IA: tumor is limited to the endometrium
- Stage IB: invasion of less than half the myometrium
- Stage IC: invasion of more than half the myometrium
- Stage IIA: endocervical glandular involvement only
- Stage IIB: cervical stromal invasion
- Stage IIIA: tumor invades serosa or adnexa, or malignant peritoneal cytology
- Stage IIIB: vaginal metastasis
- Stage IIIC: metastasis to pelvic or para-aortic lymph nodes
- Stage IVA: invasion of the bladder or bowel
- Stage IVB: distant metastasis, including intraabdominal or inguinal lymph nodes
Therapy
Therapy is based on staging and patient condition and utilizes one or more of the following approaches. Surgery is the mainstay of therapy if feasible involving total abdominal hysterectomy with bilateral salpingo-oophorectomy. Other approaches include radiation therapy, chemotherapy, and hormonal therapy.
See also
References
- ↑ Zagouri F, Dimopoulos AM, Fotiou S, Kouloulias V, Papadimitriou CA (2009). "Treatment of early uterine sarcomas: disentangling adjuvant modalities". World J Surg Oncol. 7: 38. doi:10.1186/1477-7819-7-38. PMC 2674046. PMID 19356236.
- ↑ [1] American Cancer Society information, accessed 03-11-2006
- ↑ [2] National Cancer Institute information, accessed 03-11-2006
- ↑ "uterine sarcoma".
External links
- Uni-Bonn site with detailed information, accessed 03-11-2006